Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
lochol xl
clonmel healthcare ltd - fluvastatin sodium - tablet prolonged release - 80 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
luvinsta capsules hard 20 milligram
actavis group ptc ehf - fluvastatin sodium - capsules hard - 20 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
luvinsta capsules hard 40 milligram
actavis group ptc ehf - fluvastatin sodium - capsules hard - 40 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
luvinsta xl
actavis group ptc ehf - fluvastatin sodium - tablet prolonged release - 80 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
statease capsules hard 20 milligram
mcdermott laboratories ltd t/a gerard laboratories - fluvastatin - capsules hard - 20 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
statease capsules hard 40 milligram
mcdermott laboratories ltd t/a gerard laboratories - fluvastatin - capsules hard - 40 milligram
Ирландия -
английский -
HPRA (Health Products Regulatory Authority)
statease xl
mcdermott laboratories ltd t/a gerard laboratories - fluvastatin sodium - tablet prolonged release - 80 milligram
Австралия -
английский -
Department of Health (Therapeutic Goods Administration)
lescol / lescol xl
novartis pharmaceuticals australia pty ltd - fluvastatin sodium -
Австралия -
английский -
Department of Health (Therapeutic Goods Administration)
vastin
novartis pharmaceuticals australia pty ltd - fluvastatin sodium -
Израиль -
английский -
Ministry of Health
coumadin 1 mg
taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.